PUNE, India, July 21, 2016 /PRNewswire/ --
ReportsnReports.com adds "Progressive Supranuclear Palsy - Pipeline Review, H1 2016" global market research report with comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects. It also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7, 2 and 2 respectively.
Complete report on H1 2016 pipeline review of Progressive Supranuclear Palsy with 21 market data tables and 13 figures, spread across 71 pages is available at http://www.reportsnreports.com/reports/628292-progressive-supranuclear-palsy-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Progressive Supranuclear Palsy Pipeline Review, H1 2016 report include AB Science SA, AbbVie Inc., AlzProtect SAS, Cortice Biosciences, Inc., Merck & Co., Inc., Otsuka Holdings Co., Ltd., Prana Biotechnology Limited, Sellas Inc. and TauRx Therapeutics Ltd. Drug profiles mentioned in this research report are ABBV-8E12, ASN-561, AVP-786, AZP-2006, BMS-986168, DC-TAB, DPC-016, masitinib, MK-8719, PBT-434, Small Molecules for Progressive Supranuclear Palsy, TPI-287, TRx-0237 and zolpidem tartrate.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy and reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Progressive Supranuclear Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Progressive Supranuclear Palsy.
Order a copy of Progressive Supranuclear Palsy Pipeline Review, H1 2016 report @ http://www.reportsnreports.com/Purchase.aspx?name=628292 .
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Another newly published market research report titled Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 talks about companies like AbbVie Inc., Activartis Biotech GmbH, Aduro BioTech, Inc., Advanced Accelerator Applications S.A., Advanced Cancer Therapeutics, Advantagene, Inc., Advenchen Laboratories, LLC, Affimed GmbH, Agenus, Inc., Amal Therapeutics SA, Ambrx, Inc., Amgen Inc., Ampio Pharmaceuticals, Inc., AngioChem Inc., APIM Therapeutics AS, Apogenix GmbH, Ariad Pharmaceuticals, Inc., Astellas Pharma Inc., Axelar AB, Basilea Pharmaceutica AG and more. Glioblastoma Multiforme (GBM) Pipeline market research report of 1186 pages is available at http://www.reportsnreports.com/reports/628287-glioblastoma-multiforme-gbm-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts